Metformine Huydrochloride Eg (Eurogenerics)

Metformin Hydrochloride, the active ingredient in Metformine Eg, is a biguanide presented as a tablet for oral use. It lowers elevated blood glucose by decreasing hepatic glucose production and improving peripheral insulin sensitivity, and is indicated for the management of type 2 diabetes mellitus in adult patients.

GNH USA supplies Metformine Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets. The company adheres to stringent quality standards and offers comprehensive logistics support.

Metformine Eg (metformin hydrochloride) is used in the management of disorders related to impaired glucose metabolism. - Type 2 diabetes mellitus: improves glycaemic control by reducing hepatic glucose output and enhancing insulin sensitivity. - Prediabetes (impaired glucose tolerance): delays progression to overt type 2 diabetes. - Polycystic ovary syndrome: ameliorates insulin resistance and helps regulate menstrual cycles.

Metformine Eg may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, and loss of appetite. - Diarrhoea: frequent loose stools, especially during treatment initiation. - Metallic taste: transient alteration in taste perception. - Flatulence: increased intestinal gas. - Weight loss: modest reduction in body weight. - Vitamin B12 deficiency: decreased absorption with long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic acidosis. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Hypoglycaemia: usually when combined with other glucose‑lowering agents. - Anemia: due to folate deficiency. - Electrolyte imbalance: particularly in patients with renal impairment.

Before initiating Metformine Eg, clinicians should assess patient-specific risk factors and monitor relevant parameters. - Renal function: evaluate eGFR and avoid use if severely reduced. - Hepatic function: avoid in patients with significant liver disease. - Cardiovascular status: use cautiously in heart failure due to lactic acidosis risk. - Elderly patients: start at lower dose and monitor for accumulation. - Concomitant alcohol: advise limitation to reduce lactic acidosis risk. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Metformine Eg can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations. - Alcohol: potentiates risk of lactic acidosis. - Certain antiretrovirals (e.g., didanosine): increase mitochondrial toxicity. - Loop diuretics: may impair renal clearance of metformin.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemic symptoms. - ACE inhibitors/ARBs: monitor renal function and potassium. - Warfarin: occasional alterations in INR. - Digoxin: monitor for increased serum levels. - Oral contraceptives: may slightly raise glucose levels, requiring closer glycaemic monitoring.